Ergomed's Evolution & Risk-Sharing Business Model In Practice
Executive Summary
Andrew Mackie, chief business officer of Ergomed, talks to Scrip at the recent BIO-Europe Spring partnering conference about Ergomed's transformation from a contract research organization into a drug development company.